Prelim data supports further evaluation of YTB323 in srSLE. #ACR23 Abs L13 reviews safety, CAR-T cell expansion, B cell depletion and initial efficacy in 1st 3 pts. https://t.co/aOLMhBBjgY @rheumnow https://t.co/2BoNeMe3Tg

Summary of diet effects in RA and SLE patients 👇 Dr. Sarah Patterson also shared nutrition resources for pts and clinicians https://t.co/ae6nLrLXca #ACR23 @Rheumnow @rheumarhyme @GerRheumDoc @doktora_ging https://t.co/8HhCHCTGLh

I got a chance to interview first author Jun Chu @nihrheumatology for her study on GnRHa Reducing Premature Ovarian Insufficiency in SLE pts on CYP. Watch here @RheumNow #ACR23 https://t.co/VCvAiRs4ni

Great summary of the big takeaways yesterday at #ACR23. Always love talking to @KDAO2011 @EBRheum @RheumNow We get into the use of MTX, the safety on TNFs and what is in the purview of rheumatology practice https://t.co/jm0a8ndrsi

Some studies addressing fish oil supplementation in patients w/ SLE Showed improvement in disease activity but not in serologic activity #ACR23 @RheumNow https://t.co/ANf8yMUd1b

What could CAR-T therapy mean for pts? Dr. Schett reviews 8 SLE pts, data collected since 2021 post 1 CAR-T treatment, & their marked improvement/remission of symptoms by classification criteria. Currently, he is studying a total of 15 pts (SLE, SS, myositis) #ACR23 @RheumNow https://t.co/MyMcF3PwiP

In case you missed it! Watch our ACR Monday Recap of the meeting with me, @RheumNow @EBRheum and @ericdeinmd. #ACR23 @uptoTate https://t.co/GpMdev0Yk7